Skip to main content
Erschienen in: Neuroethics 2/2012

01.08.2012 | Original Paper

Ethical Considerations in the Framing of the Cognitive Enhancement Debate

verfasst von: Simon M. Outram

Erschienen in: Neuroethics | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Over the past few years the use of stimulants such as methylphenidate and modafinil among the student population has attracted considerable debate in the pages of bioethics journals. Under the rubric of cognitive enhancement, bioethicists have discussed this use of stimulants—along with future technologies of enhancement—and have launched a sometimes forceful debate of such practices. In the following paper, it is argued that even if we focus solely upon current practices, the term cognitive enhancement encompasses a wide range of ethical considerations that can usefully be addressed without the need for speculation. In taking this position it is suggested that we divide cognitive enhancement into a series of empirically-constructed frameworks—medical risks and benefits, self-medication and under-prescription, prescription drug abuse and over-medication, and finally, the intention to cognitively enhance. These are not mutually exclusive frameworks, but provide a way in which to identify the scope of the issue at hand and particular ethical and medical questions that may be relevant to enhancement. By a process of elimination it is suggested that we can indeed talk of cognitive enhancement as an observable set of practices. However, in doing so we should be aware of how academic commentaries and discussion may be seen as both capturing reality and reifying cognitive enhancement as an entity.
Literatur
1.
Zurück zum Zitat Baylis, F., and J.S. Robert. 2004. The inevitability of genetic enhancement technologies. Bioethics 18(1): 1–26.CrossRef Baylis, F., and J.S. Robert. 2004. The inevitability of genetic enhancement technologies. Bioethics 18(1): 1–26.CrossRef
2.
Zurück zum Zitat Bostrom, Nick, and Anders Sandberg. 2009. Cognitive enhancement: Methods, ethics, regulatory challenges. Science & Engineering Ethics 15(3): 311–341.CrossRef Bostrom, Nick, and Anders Sandberg. 2009. Cognitive enhancement: Methods, ethics, regulatory challenges. Science & Engineering Ethics 15(3): 311–341.CrossRef
3.
Zurück zum Zitat Cakic, V. 2009. Smart drugs for cognitive enhancement: Ethical and pragmatic considerations in the era of cosmetic neurology. Journal of Medical Ethics 35(10): 611–615.CrossRef Cakic, V. 2009. Smart drugs for cognitive enhancement: Ethical and pragmatic considerations in the era of cosmetic neurology. Journal of Medical Ethics 35(10): 611–615.CrossRef
4.
Zurück zum Zitat Chatterjee, A. 2006. The promise and predicament of cosmetic neurology. Journal of Medical Ethics 32: 110e13. Chatterjee, A. 2006. The promise and predicament of cosmetic neurology. Journal of Medical Ethics 32: 110e13.
5.
Zurück zum Zitat Farah, Martha J., Judy Illes, Robert Cook-Deegan, Howard Gardner, Eric Kandel, Patricia King, Eric Parens, Barbara Sahakian, and Paul Root Wolpe. 2004. Neurocognitive enhancement: What can we do and what should we do? Nature Reviews: Neuroscience: 421–5. Farah, Martha J., Judy Illes, Robert Cook-Deegan, Howard Gardner, Eric Kandel, Patricia King, Eric Parens, Barbara Sahakian, and Paul Root Wolpe. 2004. Neurocognitive enhancement: What can we do and what should we do? Nature Reviews: Neuroscience: 421–5.
6.
Zurück zum Zitat Sahakian, B.J., and S. Morein-Zamir. 2011. Neuroethical issues in cognitive enhancement. Journal of Psychopharmacology 25(2): 197–204.CrossRef Sahakian, B.J., and S. Morein-Zamir. 2011. Neuroethical issues in cognitive enhancement. Journal of Psychopharmacology 25(2): 197–204.CrossRef
7.
Zurück zum Zitat Jones, D.G. 2006. Enhancement: Are ethicists excessively influenced by baseless speculations? Medical Humanities 32(2): 77–81.CrossRef Jones, D.G. 2006. Enhancement: Are ethicists excessively influenced by baseless speculations? Medical Humanities 32(2): 77–81.CrossRef
8.
Zurück zum Zitat Hall, W.D., and J.C. Lucke. 2010. The enhancement use of neuropharmaceuticals: More scepticism and caution needed. Addication 105: 2041–2043.CrossRef Hall, W.D., and J.C. Lucke. 2010. The enhancement use of neuropharmaceuticals: More scepticism and caution needed. Addication 105: 2041–2043.CrossRef
9.
Zurück zum Zitat Williams, S.J., and P. Martin. 2009. Risks and benefits may turn out to be finely balanced. Nature 457: 532.CrossRef Williams, S.J., and P. Martin. 2009. Risks and benefits may turn out to be finely balanced. Nature 457: 532.CrossRef
10.
11.
Zurück zum Zitat Hotze, T.D., K. Shah, E.E. Anderson, and M.K. Wynia. 2011. “Doctor, would you prescribe a pill to help me…?” A national survey of physicians on using medicine for human enhancement. American Journal of Bioethics 11(1): 3–13.CrossRef Hotze, T.D., K. Shah, E.E. Anderson, and M.K. Wynia. 2011. “Doctor, would you prescribe a pill to help me…?” A national survey of physicians on using medicine for human enhancement. American Journal of Bioethics 11(1): 3–13.CrossRef
12.
Zurück zum Zitat Larriviere, Dan J.D., Michael A.F.A.A.N. Williams, Matt F.A.A.N. Rizzo, and Richard J.L.L.B. Bonnie. 2009. Responding to requests from adult patients for neuroenhancements: Guidance of the ethics, law and humanities committee. Neurology 73(17): 1406–1412.CrossRef Larriviere, Dan J.D., Michael A.F.A.A.N. Williams, Matt F.A.A.N. Rizzo, and Richard J.L.L.B. Bonnie. 2009. Responding to requests from adult patients for neuroenhancements: Guidance of the ethics, law and humanities committee. Neurology 73(17): 1406–1412.CrossRef
13.
Zurück zum Zitat Farah, M.J., C. Haimm, G. Sankoorikal, and A. Chatterjee. 2009. When we enhance cognition with adderall, do we sacrifice creativity? A preliminary study. Psychopharmacology. 202(1): 541–547.CrossRef Farah, M.J., C. Haimm, G. Sankoorikal, and A. Chatterjee. 2009. When we enhance cognition with adderall, do we sacrifice creativity? A preliminary study. Psychopharmacology. 202(1): 541–547.CrossRef
15.
Zurück zum Zitat Advokat, C.D., D. Guidry, and L. Martino. 2008. Licit and illicit use of medications for attention-deficit hyperactivity disorder in undergraduate college students. Journal of American College Health 56(6): 601–606.CrossRef Advokat, C.D., D. Guidry, and L. Martino. 2008. Licit and illicit use of medications for attention-deficit hyperactivity disorder in undergraduate college students. Journal of American College Health 56(6): 601–606.CrossRef
16.
Zurück zum Zitat Barrett, S.P., C. Darredeau, L.E. Bordy, and R.O. Pihl. 2005. Characteristics of methylphenidate misuse in a university student sample. Canadian Journal of Psychiatry 50(8): 457–461. Barrett, S.P., C. Darredeau, L.E. Bordy, and R.O. Pihl. 2005. Characteristics of methylphenidate misuse in a university student sample. Canadian Journal of Psychiatry 50(8): 457–461.
17.
Zurück zum Zitat McCabe, S.E., J.R. Knight, C.J. Teter, and H. Wechsler. 2005. Non-medical use of prescription stimulants among US college students: Prevalence and correlates from a national survey. Addiction 100(1): 96–106.CrossRef McCabe, S.E., J.R. Knight, C.J. Teter, and H. Wechsler. 2005. Non-medical use of prescription stimulants among US college students: Prevalence and correlates from a national survey. Addiction 100(1): 96–106.CrossRef
18.
Zurück zum Zitat Teter, C.J., S.E. McCabe, J.A. Cranford, C.J. Boyd, and S.K. Guthrie. 2005. Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample. Journal of American College Health 53(6): 253–262.CrossRef Teter, C.J., S.E. McCabe, J.A. Cranford, C.J. Boyd, and S.K. Guthrie. 2005. Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample. Journal of American College Health 53(6): 253–262.CrossRef
19.
Zurück zum Zitat White, B.P., K.A. Becker-Blease, and K. Grace-Bishop. 2006. Stimulant medication use, misuse, and abuse in an undergraduate and graduate student sample. Journal of American College Health 54(5): 261–268.CrossRef White, B.P., K.A. Becker-Blease, and K. Grace-Bishop. 2006. Stimulant medication use, misuse, and abuse in an undergraduate and graduate student sample. Journal of American College Health 54(5): 261–268.CrossRef
20.
Zurück zum Zitat Outram, S.M. 2010. The use of methylphenidate among students: The future of enhancement? Journal of Medical Ethics. 36(4): 198–202.CrossRef Outram, S.M. 2010. The use of methylphenidate among students: The future of enhancement? Journal of Medical Ethics. 36(4): 198–202.CrossRef
21.
Zurück zum Zitat Johnston, L. D., O’Malley, P. M., Bachman, J. G., and Schulenberg, J. E. 2010. Monitoring the Future national survey results on drug use, 1975–2009: Volume II, College students and adults ages 19–50 (NIH Publication No. 10–7585). Bethesda, MD:National Institute on Drug Abuse. Table 2–2. Johnston, L. D., O’Malley, P. M., Bachman, J. G., and Schulenberg, J. E. 2010. Monitoring the Future national survey results on drug use, 19752009: Volume II, College students and adults ages 19–50 (NIH Publication No. 10–7585). Bethesda, MD:National Institute on Drug Abuse. Table 2–2.
22.
Zurück zum Zitat Maher, B. 2008. Poll results: Look who's doping. Nature 452: 674–675.CrossRef Maher, B. 2008. Poll results: Look who's doping. Nature 452: 674–675.CrossRef
23.
Zurück zum Zitat Johnston, L. D., O’Malley, P. M., Bachman, J. G., and Schulenberg, J. E. 2010. Monitoring the Future national survey results on drug use, 1975–2009: Volume II, College students and adults ages 19–50 (NIH Publication No. 10–7585). Bethesda, MD:National Institute on Drug Abuse. Table 2–2 p.47. Johnston, L. D., O’Malley, P. M., Bachman, J. G., and Schulenberg, J. E. 2010. Monitoring the Future national survey results on drug use, 19752009: Volume II, College students and adults ages 19–50 (NIH Publication No. 10–7585). Bethesda, MD:National Institute on Drug Abuse. Table 2–2 p.47.
24.
Zurück zum Zitat Rabiner, D.L., A.D. Anastopoulos, E. Jane Costello, R.H. Hoyle, S.E. McCabe, and H. Scott Swartzwelder. 2009. Motives and perceived consequences of nonmedical ADHD medication use by college students. Journal of Attention Disorders 13(3): 259–270.CrossRef Rabiner, D.L., A.D. Anastopoulos, E. Jane Costello, R.H. Hoyle, S.E. McCabe, and H. Scott Swartzwelder. 2009. Motives and perceived consequences of nonmedical ADHD medication use by college students. Journal of Attention Disorders 13(3): 259–270.CrossRef
25.
Zurück zum Zitat Repantis, Dimitris, Schlattmann Peter, Laisney Oona, and Heuser Isabella. 2010. Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review. Pharmacological Research 62(3): 187–206.CrossRef Repantis, Dimitris, Schlattmann Peter, Laisney Oona, and Heuser Isabella. 2010. Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review. Pharmacological Research 62(3): 187–206.CrossRef
26.
Zurück zum Zitat Efron, Daryl, Frederick Jarman, and Melinda Barker. 1997. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial. Pediatrics 100(4): 662–666.CrossRef Efron, Daryl, Frederick Jarman, and Melinda Barker. 1997. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial. Pediatrics 100(4): 662–666.CrossRef
27.
Zurück zum Zitat Godfrey, J. 2009. Safety of therapeutic methylphenidate in adults: A systematic review of the evidence. Journal of Psychopharmacology 23(2): 194–205.CrossRef Godfrey, J. 2009. Safety of therapeutic methylphenidate in adults: A systematic review of the evidence. Journal of Psychopharmacology 23(2): 194–205.CrossRef
28.
Zurück zum Zitat Kooij, J.J.S., H. Burger, A.M. Boonstra, P.D. Van Der Linden, L.E. Kalma, and J.K. Buitelaar. 2004. Efficacy and Safety Of Methylphenidate in 45 Adults With attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine 34(6): 973–982.CrossRef Kooij, J.J.S., H. Burger, A.M. Boonstra, P.D. Van Der Linden, L.E. Kalma, and J.K. Buitelaar. 2004. Efficacy and Safety Of Methylphenidate in 45 Adults With attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine 34(6): 973–982.CrossRef
29.
Zurück zum Zitat Kollins, S.H., E.K. MacDonald, and C.R. Rush. 2001. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacology, Biochemistry and Behavior 68: 611–627.CrossRef Kollins, S.H., E.K. MacDonald, and C.R. Rush. 2001. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacology, Biochemistry and Behavior 68: 611–627.CrossRef
30.
Zurück zum Zitat Schermer, M., I. Bolt, R. de Jong, and B. Olivier. 2009. The future of psychopharmacological enhancements: Expectations and policies. Neuroethics 2 (2): 75–87 Schermer, M., I. Bolt, R. de Jong, and B. Olivier. 2009. The future of psychopharmacological enhancements: Expectations and policies. Neuroethics 2 (2): 75–87
31.
Zurück zum Zitat Randall, Delia C., John M. Shneerson, and Sandra E. File. 2005. Cognitive effects of modafinil in student volunteers may depend on IQ. Pharmacology Biochemistry and Behavior 82(1): 133–139.CrossRef Randall, Delia C., John M. Shneerson, and Sandra E. File. 2005. Cognitive effects of modafinil in student volunteers may depend on IQ. Pharmacology Biochemistry and Behavior 82(1): 133–139.CrossRef
33.
Zurück zum Zitat Poulin, C. 2007. From attention-deficit/hyperactivity disorder to medical stimulant use to the diversion of prescribed stimulants to non-medical stimulant use: Connecting the dots. Addiction 102(5): 740–751.CrossRef Poulin, C. 2007. From attention-deficit/hyperactivity disorder to medical stimulant use to the diversion of prescribed stimulants to non-medical stimulant use: Connecting the dots. Addiction 102(5): 740–751.CrossRef
34.
Zurück zum Zitat Wilens, T.E., L.A. Adler, J. Adams, S. Sgambati, J. Rotrosen, R. Sawtelle, L. Utzinger, and S. Fusillo. 2008. Misuse and diversion of stimulants prescribed for ADHD: A systematic review of the literature. Journal of the American Academy of Child & Adolescent Psychiatry 47(1): 21–31.CrossRef Wilens, T.E., L.A. Adler, J. Adams, S. Sgambati, J. Rotrosen, R. Sawtelle, L. Utzinger, and S. Fusillo. 2008. Misuse and diversion of stimulants prescribed for ADHD: A systematic review of the literature. Journal of the American Academy of Child & Adolescent Psychiatry 47(1): 21–31.CrossRef
36.
Zurück zum Zitat Kessler, Ronald C., Lenard Adler, Russell Barkley, Joseph Biederman, C.Keith Conners, Olga Demler, and Stephen V. Faraone. 2006. The prevalence and correlates of adult ADHD in the united states: Results from the national comorbidity survey replication. American Journal of Psychiatry 163: 716–723.CrossRef Kessler, Ronald C., Lenard Adler, Russell Barkley, Joseph Biederman, C.Keith Conners, Olga Demler, and Stephen V. Faraone. 2006. The prevalence and correlates of adult ADHD in the united states: Results from the national comorbidity survey replication. American Journal of Psychiatry 163: 716–723.CrossRef
37.
Zurück zum Zitat Faraone, S.V., and J. Biederman. 2005. What is the prevalence of adult ADHD? results of a population screen of 966 adults. Journal of Attention Disorders 9(2): 384–391.CrossRef Faraone, S.V., and J. Biederman. 2005. What is the prevalence of adult ADHD? results of a population screen of 966 adults. Journal of Attention Disorders 9(2): 384–391.CrossRef
38.
Zurück zum Zitat Fayyad, J., R. De Graaf, R. Kessler, J. Alonso, M. Angermeyer, K. Demyttenaere, G. De Girolamo, et al. 2007. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. The British Journal of Psychiatry 190(5): 402–409.CrossRef Fayyad, J., R. De Graaf, R. Kessler, J. Alonso, M. Angermeyer, K. Demyttenaere, G. De Girolamo, et al. 2007. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. The British Journal of Psychiatry 190(5): 402–409.CrossRef
39.
Zurück zum Zitat Racine, E., and C. Forlini. 2010. Cognitive enhancement, lifestyle choice or misuse of prescription drugs? Neuroethics 3(1): 1–4.CrossRef Racine, E., and C. Forlini. 2010. Cognitive enhancement, lifestyle choice or misuse of prescription drugs? Neuroethics 3(1): 1–4.CrossRef
41.
Zurück zum Zitat Boyd, C.J., S.E. McCabe, J.A. Cranford, and A. Young. 2007. Prescription drug abuse and diversion among adolescents in a southeast michigan school district. Archives of Pediatrics Adolescent Medicine 161(3): 276–281.CrossRef Boyd, C.J., S.E. McCabe, J.A. Cranford, and A. Young. 2007. Prescription drug abuse and diversion among adolescents in a southeast michigan school district. Archives of Pediatrics Adolescent Medicine 161(3): 276–281.CrossRef
42.
Zurück zum Zitat Fischer, B., M. Bibby, and M. Bouchard. 2010. The global diversion of pharmaceutical drugs non-medical use and diversion of psychotropic prescription drugs in north america: A review of sourcing routes and control measures. Addiction 105(12): 2062–2070.CrossRef Fischer, B., M. Bibby, and M. Bouchard. 2010. The global diversion of pharmaceutical drugs non-medical use and diversion of psychotropic prescription drugs in north america: A review of sourcing routes and control measures. Addiction 105(12): 2062–2070.CrossRef
43.
Zurück zum Zitat Harrison, A.G., M.J. Edwards, and K.C.H. Parker. 2007. Identifying students faking ADHD: Preliminary findings and strategies for detection. Archives of Clinical Neuropsychology 22(5): 577–588.CrossRef Harrison, A.G., M.J. Edwards, and K.C.H. Parker. 2007. Identifying students faking ADHD: Preliminary findings and strategies for detection. Archives of Clinical Neuropsychology 22(5): 577–588.CrossRef
44.
Zurück zum Zitat Booksh, R.L., R.D. Pella, A.N. Singh, and W.D. Gouvier. 2010. Ability of college students to simulate ADHD on objective measures of attention. Journal of Attention Disorders 13(4): 325–338.CrossRef Booksh, R.L., R.D. Pella, A.N. Singh, and W.D. Gouvier. 2010. Ability of college students to simulate ADHD on objective measures of attention. Journal of Attention Disorders 13(4): 325–338.CrossRef
45.
Zurück zum Zitat Sullivan, B.K., May Kim, and L. Galbally. 2007. Symptom exaggeration by college adults in attention-deficit hyperactivity disorder and learning disorder assessments. Applied Neuropsychology 14(3): 189–207.CrossRef Sullivan, B.K., May Kim, and L. Galbally. 2007. Symptom exaggeration by college adults in attention-deficit hyperactivity disorder and learning disorder assessments. Applied Neuropsychology 14(3): 189–207.CrossRef
46.
Zurück zum Zitat Mittenberg, W., C. Patton, E.M. Canyock, D.C. Condit, and W. Mittenberg. 2002. Base rates of malingering and symptom exaggeration. Journal of Clinical and Experimental Neuropsychology. 24(8): 1094–1102.CrossRef Mittenberg, W., C. Patton, E.M. Canyock, D.C. Condit, and W. Mittenberg. 2002. Base rates of malingering and symptom exaggeration. Journal of Clinical and Experimental Neuropsychology. 24(8): 1094–1102.CrossRef
47.
Zurück zum Zitat Soliman, M.J., J.D. Ranseen, T. David, and R. Berry. 2010. Detection of feigned ADHD in college students. Psychological Assessment. 22(2): 325–335.CrossRef Soliman, M.J., J.D. Ranseen, T. David, and R. Berry. 2010. Detection of feigned ADHD in college students. Psychological Assessment. 22(2): 325–335.CrossRef
48.
Zurück zum Zitat Greely, Henry, B. Sahakian, J. Harri, R.C. Kessler, M. Gazzaniga, P. Campbell, and Marth J. Farah. 2008. Towards responsible use of cognitiveenhancing drugs by the healthy. Nature 456: 702e5.CrossRef Greely, Henry, B. Sahakian, J. Harri, R.C. Kessler, M. Gazzaniga, P. Campbell, and Marth J. Farah. 2008. Towards responsible use of cognitiveenhancing drugs by the healthy. Nature 456: 702e5.CrossRef
51.
Zurück zum Zitat Hall, K.M., M.M. Irwin, K.A. Bowman, W. Frankenberger, and D.C. Jewett. 2005. Illicit use of prescribed stimulant medication among college students. Journal of American College Health 53(4): 167–174.CrossRef Hall, K.M., M.M. Irwin, K.A. Bowman, W. Frankenberger, and D.C. Jewett. 2005. Illicit use of prescribed stimulant medication among college students. Journal of American College Health 53(4): 167–174.CrossRef
52.
Zurück zum Zitat Chadwick, Ruth Therapy, Enhancement and Improvement. In: Ruth Chadwick B. Gordijn, R. Chadwick (eds.) Medical Enhancement and Posthumanity. Springer Science & Business Media BV. Chadwick, Ruth Therapy, Enhancement and Improvement. In: Ruth Chadwick B. Gordijn, R. Chadwick (eds.) Medical Enhancement and Posthumanity. Springer Science & Business Media BV.
53.
Zurück zum Zitat Daniels, N. 2000. Normal functioning and the treatment-enhancement distinction. Cambridge Quarterly of Healthcare Ethics 9(3): 309–322.CrossRef Daniels, N. 2000. Normal functioning and the treatment-enhancement distinction. Cambridge Quarterly of Healthcare Ethics 9(3): 309–322.CrossRef
54.
Zurück zum Zitat Rasmussen, N. 2006. Making the First Anti-Depressant: Amphetamine in American Medicine, 1929–1950. Journal of The History Of Medicine and Allied Sciences 61(3): 288–323.CrossRef Rasmussen, N. 2006. Making the First Anti-Depressant: Amphetamine in American Medicine, 1929–1950. Journal of The History Of Medicine and Allied Sciences 61(3): 288–323.CrossRef
55.
Zurück zum Zitat Canu, W.H., M.L. Newman, T.L. Morrow, and Daniel L .W. Pope. 2008. Social appraisal of adult ADHD. Journal of Attention Disorders 11(6): 700–710.CrossRef Canu, W.H., M.L. Newman, T.L. Morrow, and Daniel L .W. Pope. 2008. Social appraisal of adult ADHD. Journal of Attention Disorders 11(6): 700–710.CrossRef
56.
Zurück zum Zitat Inciardi, James A., Hilary L. Surratt, Steven P. Kurtz, and Theodore J. Cicero. 2007. Mechanisms of prescription drug diversion among drug-involved club and street-based populations. Pain Medicine 8(2): 171–183. Inciardi, James A., Hilary L. Surratt, Steven P. Kurtz, and Theodore J. Cicero. 2007. Mechanisms of prescription drug diversion among drug-involved club and street-based populations. Pain Medicine 8(2): 171–183.
57.
Zurück zum Zitat Downie, J., S. Outram, and F. Campbell. 2010. Caveat Emptor, Venditor, Et Praescribor: Legal Liability Associated With Methyplenidate Hydrochloride (MPH) Use By Postsecondary Students. Health Law Journal 18: 51–71. Downie, J., S. Outram, and F. Campbell. 2010. Caveat Emptor, Venditor, Et Praescribor: Legal Liability Associated With Methyplenidate Hydrochloride (MPH) Use By Postsecondary Students. Health Law Journal 18: 51–71.
58.
Zurück zum Zitat Forlini, Cynthia and E. Racine. 2009. Autonomy and Coercion in Academic “Cognitive Enhancement” Using Methylphenidate: Perspectives of Key Stakeholders Neuroethics 2:163–177. Forlini, Cynthia and E. Racine. 2009. Autonomy and Coercion in Academic “Cognitive Enhancement” Using Methylphenidate: Perspectives of Key Stakeholders Neuroethics 2:163–177.
59.
Zurück zum Zitat Hall, W. 2004. Feeling 'better than well'. EMBO Reports 5(12): 1105–1109.CrossRef Hall, W. 2004. Feeling 'better than well'. EMBO Reports 5(12): 1105–1109.CrossRef
Metadaten
Titel
Ethical Considerations in the Framing of the Cognitive Enhancement Debate
verfasst von
Simon M. Outram
Publikationsdatum
01.08.2012
Verlag
Springer Netherlands
Erschienen in
Neuroethics / Ausgabe 2/2012
Print ISSN: 1874-5490
Elektronische ISSN: 1874-5504
DOI
https://doi.org/10.1007/s12152-011-9131-7

Weitere Artikel der Ausgabe 2/2012

Neuroethics 2/2012 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.